Filana Therapeutics (FLNA) EBIT (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly EBIT of -$9.4 million for Q2 2026, up 79.31% year-over-year from -$5.2 million in Q2 2025, and up 15.89% quarter-over-quarter from -$11.2 million in Q1 2026.
Filana Therapeutics (FLNA) EBIT (2010 - 2026) Analysis & Trends
Filana Therapeutics' EBIT history runs 17 years deep, the most recent figure standing at -$9.4 million for Q2 2026.
- In Q2 2026, EBIT rose 79.31% year-over-year to -$9.4 million; the TTM figure through Jun 2026 stood at -$46.0 million (up 64.66% YoY), while the FY2025 annual figure was -$95.4 million, up 32.56% from the prior year.
- EBIT for Q2 2026 stood at -$9.4 million, up from -$11.2 million in the prior quarter.
- The five-year high for EBIT was -$9.4 million in Q2 2026, with the low at -$61.4 million in Q2 2024.
- The 5-year median for EBIT is -$22.1 million (2022), against an average of -$24.6 million.
- The sharpest annual moves came in 2022 and 2026: EBIT plunged 404.42% in 2022, then surged 79.31% in 2026.
- Filana Therapeutics' EBIT stood at -$20.9 million in 2022, then slipped by 8.85% to -$22.8 million in 2023, then slipped by 29.39% to -$29.5 million in 2024, then surged by 54.04% to -$13.6 million in 2025, then surged by 30.69% to -$9.4 million in 2026.
- Business Quant data shows FLNA's EBIT at -$9.4 million in Q2 2026, -$11.2 million in Q1 2026, and -$13.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Filana Therapeutics | 46.14 Mn | 46.14 Mn | - | -9.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.39 Mn |
| Mar 31, 2026 | -11.17 Mn |
| Dec 31, 2025 | -13.55 Mn |
| Sep 30, 2025 | -11.86 Mn |
| Jun 30, 2025 | -45.39 Mn |
| Mar 31, 2025 | -24.59 Mn |
| Dec 31, 2024 | -29.49 Mn |
| Sep 30, 2024 | -30.62 Mn |
| Jun 30, 2024 | -61.40 Mn |
| Mar 31, 2024 | -19.93 Mn |
| Dec 31, 2023 | -22.79 Mn |
| Sep 30, 2023 | -27.88 Mn |
| Jun 30, 2023 | -28.78 Mn |
| Mar 31, 2023 | -26.51 Mn |
| Dec 31, 2022 | -20.94 Mn |
| Sep 30, 2022 | -21.35 Mn |
| Jun 30, 2022 | -19.92 Mn |
| Mar 31, 2022 | -17.82 Mn |
| Dec 31, 2021 | -14.44 Mn |
| Sep 30, 2021 | -9.75 Mn |